Capivasertib plus Faslodex significantly improved progression-free survival vs Faslodex in CAPItello-291 phase III trial in advanced HR-positive breast cancer
Pharmabiz.com,
Positive high-level results from the CAPItello-291 phase III trial showed that AstraZeneca’s capivasertib in combination with…